Kyverna Therapeutics, Inc.
NASDAQ:KYTXBiotechnology
-$0.12 today
- Market cap
- $283.23M
- Beta
- 1.96
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$2.59
Volume 1.05M
Average 0.94M
KYTX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Kyverna Therapeutics, Inc.NASDAQ: KYTX
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 43.4% from a year ago
Cash & equivalents stood at $32.19M at the end of Q1 FY2026, down 43.4% from a year earlier and down 74.1% from the prior quarter. Over 3 fiscal years it compounded at +48.7% a year.
Context
- Cash & equivalents amounted to 12.5% of total assets at the end of Q1 FY2026, down 9.3 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -43.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 124.09M USD
- Year-over-year change
- +28.4%
- 4-year CAGR
- +13.0%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 124.09M | +28.4% |
| FY2024 | 2024-12-31 | 96.62M | +178.9% |
| FY2023 | 2023-12-31 | 34.65M | -8.2% |
| FY2022 | 2022-12-31 | 37.74M | -50.4% |
| FY2021 | 2021-12-31 | 76.07M | — |
Cash & Equivalents vs competitors
How KYTX compares with its peers on the latest reported figures
- KYTX's Mar 2026 cash & equivalents of $32.19M is the 8th highest of the 11 companies compared; the peer median is $75.54M.
- Its year-over-year change of -43.4% is the 10th highest of 11, against a peer median of -18.0%.
- Cash & equivalents amounts to 12.5% of total assets for KYTX, versus a peer median of 29.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $123.65M | -10.8% | +1.2% | 82.8% | |
| Mar 2026 | $116.64M | -11.5% | +0.6% | 78.7% | |
| Mar 2026 | $105.42M | +266.1% | +210.6% | 32.3% | |
| Mar 2026 | $90.77M | -24.6% | -21.3% | 25.9% | |
| Mar 2026 | $79.32M | -33.6% | -47.1% | 29.7% | |
LXEOLexeo Therapeutics, Inc. Common Stock | Mar 2026 | $71.77M | +148.2% | -6.6% | 28.7% |
| Mar 2026 | $36.22M | -42.0% | -15.6% | 89.2% | |
| Mar 2026 | $32.19M | -43.4% | +48.7% | 12.5% | |
| Mar 2026 | $30.31M | -28.6% | -5.8% | 7.7% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $20.16M | -10.3% | +138.6% | 7.7% |
| Mar 2026 | $5.66M | -91.3% | -41.0% | 4.9% | |
| Peer median (excluding KYTX) | $75.54M | -18.0% | -6.2% | 29.2% | |
Competitors are the stored peer set for KYTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 76.07M | 37.74M | 34.65M | 96.62M | 124.09M |
| Short-term Investments | 0 | 13.59M | 22.9M | 189.36M | 155.16M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.02M | 1.93M | 3.12M | 4.62M | 3.7M |
| Total Current Assets | 77.09M | 53.25M | 60.66M | 290.6M | 282.95M |
| Property, Plant & Equipment (Net) | 7.81M | 12.44M | 10.61M | 10.66M | 5.42M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 593K | 1.23M | 3.92M | 5.26M | 5.45M |
| Total Non-current Assets | 8.4M | 13.67M | 14.53M | 15.92M | 10.87M |
| Total Assets | 85.49M | 66.92M | 75.2M | 304.65M | 293.83M |
| Account Payables | 773K | 1.45M | 4.36M | 4.62M | 5.31M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 6M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.72M | 565K | 9.77M | 4.88M | 9.99M |
| Total Current Liabilities | 15.93M | 11.95M | 19.86M | 33.76M | 36.49M |
| Long-term Debt | 0 | 0 | 0 | 0 | 24.74M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 1.03M | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 110.05M | 6K | 0 | 0 | 0 |
| Total Non-current Liabilities | 115.81M | 8.29M | 6.16M | 4.3M | 25.06M |
| Total Liabilities | 131.74M | 20.25M | 26.02M | 38.06M | 61.55M |
| Common Stock | 0 | 0 | 0 | 0 | 1K |
| Retained Earnings | (46.78M) | (75.68M) | (136.04M) | (263.52M) | (424.83M) |
| Accumulated OCI | 0 | (26K) | 4K | 105K | 97K |
| Other Stockholders Equity | 0 | (0) | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (46.25M) | 46.68M | 49.18M | 266.59M | 232.28M |
| Total Debt | 5.56M | 10.56M | 9.08M | 8.24M | 29.03M |
| Net Debt | (70.51M) | (27.17M) | (25.57M) | (88.38M) | (95.06M) |
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
Intrinsic Alpha fair value
Locked
Current Price
$4.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.